Adalimumab therapy for psoriasis in korean patients: an interim report = Adalimumab therapy for psoriasis in korean patients: an interim report

다국어 초록 (Multilingual Abstract)

Background: Adalimumab, the first fully human tumor necrosis factor alpha (TNF-a) monoclonal antibody is widely used to manage moderate to severe chronic plaque psoriasis. Up to now, data are lacking on the use of adalimumab for psoriasis treatment in the Korean. Objectives: To estimate the efficacy and safety of adalimumab in Korean psoriasis patients and compare this results with other studies. Methods: Total 10 patients treated with adalimumab were enrolled. Medical data was retrospectively collected from March 2011 to July 2013. All patients were injected adalimumab 80 mg given subcutaneously the first week, followed by 40 mg subcutaneously given the next week and then every other week. Data including Psoriasis Area and Severity Index (PASI), and any adverse event were recorded every visit. Results: Eight patients of 9, receiving adalimumab 16 weeks, achieved PASI 75 at 16 week. In the remaining 1 patient, a patient achieved PASI 75 at 18 week and another patient discontinued adalimumab due to upper respiratory infection, any adverse event causally related to the treatment was not reported in the 16 weeks treatment period. In this study, overall 89% (n=8/9) of patients achieved PASI 75 at 16 week and all patients well tolerated to adlimumab treatment. And PASI 75 and 90 at 74 week were 100% (n=5/5) and 80% (n=4/5) respectively. Conclusion: Ongoing study will include more patients and determine long term efficacy and safety of adalimumab treatment in the Korean psoriasis patients.